Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3

<b>Background:</b> Targeted therapies (e.g., ibrutinib) have markedly improved chronic lymphocytic leukemia (CLL) management; however, ~20% of patients experience disease relapse, suggesting the inadequate depth and durability of these front-line strategies. Moreover, immunotherapeutic s...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Biomedicines
المؤلفون الرئيسيون:	Elizabeth Schmitz, Abigail Ridout, Audrey L. Smith, Alexandria P. Eiken, Sydney A. Skupa, Erin M. Drengler, Sarbjit Singh, Sandeep Rana, Amarnath Natarajan, Dalia El-Gamal
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2024-12-01
الموضوعات:	chronic lymphocytic leukemia (CLL) SpiD3 immunogenic cell death (ICD) damage-associated molecular patterns (DAMPs) ferroptosis oxidative stress
الوصول للمادة أونلاين:	https://www.mdpi.com/2227-9059/12/12/2857